Aurinia v. Teva: LUPKYNIS® Patent Case Consolidated After 222 Days
Aurinia Pharmaceuticals filed suit against Teva in the District of New Jersey asserting two patents covering voclosporin — the active ingredient in its LUPKYNIS® lupus nephritis drug. After 222 days, the court consolidated this action with related Case No. 25-2580, which now serves as the Lead Case for all pre-trial proceedings.
ANDA Battle Over Voclosporin Absorbed Into Lead NJ Consolidation
On April 25, 2025, Aurinia Pharmaceuticals, Inc. filed suit against Teva Pharmaceutical Industries, Ltd. in the U.S. District Court for the District of New Jersey, asserting infringement of U.S. Patent Nos. 11622991B2 and 10286036B2. Both patents relate to voclosporin, the calcineurin inhibitor at the core of Aurinia’s FDA-approved LUPKYNIS® product, the first oral therapy specifically approved for lupus nephritis. The filing follows Teva’s submission of an Abbreviated New Drug Application (ANDA) seeking approval for a generic version of LUPKYNIS®.
On December 3, 2025 — 222 days after filing — the court entered a consolidation order under Federal Rule of Civil Procedure 42 and Local Civil Rule 42.1, merging this action with related proceedings into a single Consolidated Action. Civil Action No. 25-2580 was designated the Lead Case, and all future filings must be made there. Consolidation was unopposed by all parties and was grounded in the court’s finding of common questions of law and fact across the related actions.
The rapid move to consolidation — under seven months — suggests Teva is not the only generic filer challenging Aurinia’s voclosporin patent estate, and that the District of New Jersey is managing a wave of ANDA litigation over LUPKYNIS® in a coordinated fashion. The substantive merits, including validity and infringement of both asserted patents, remain unresolved. The public record does not disclose the terms of any licensing discussions or the identity of all co-defendants in the consolidated proceeding.
Filing to Case Consolidated in 222 days
222 days before consolidation — typical ANDA first-instance cases often run 24–36 months to trial
What consolidation into Lead Case 25-2580 means for both parties
Consolidation under Rule 42: one case, one judge, one schedule
Federal Rule of Civil Procedure 42(a) permits a court to consolidate actions sharing common questions of law or fact. Here, the court found that this action and the Lead Case (25-2580) are sufficiently related — almost certainly because multiple generic manufacturers filed ANDAs for LUPKYNIS® around the same time. All pre-trial proceedings, including discovery and case management, now proceed under a single docket, conserving judicial and party resources.
Procedural consolidationAurinia secures coordinated defence of its voclosporin IP estate
Consolidation typically benefits the brand-name plaintiff in ANDA litigation: it enables Aurinia to pursue discovery, claim construction, and trial preparation against multiple generic challengers simultaneously under one coordinated schedule. Both asserted patents remain in force and fully enforceable. The 30-month stay under Hatch-Waxman, triggered by Aurinia’s timely suit, continues to run, barring FDA approval of Teva’s generic during that period absent a court order.
Patents remain enforceableTeva faces consolidated proceedings alongside other ANDA filers
Teva’s path to market for a LUPKYNIS® generic now runs through the consolidated action in Lead Case 25-2580. Consolidation means Teva’s litigation strategy — including its invalidity and non-infringement positions — will be developed alongside any other generic defendants, potentially limiting its ability to pursue a wholly independent schedule. However, consolidation does not resolve the merits, and Teva retains all its substantive defences.
Merits unresolvedCoordinated ANDA wave signals competitive pressure on LUPKYNIS® exclusivity
The need to consolidate multiple actions this early in the litigation lifecycle suggests that several generic manufacturers have targeted LUPKYNIS® simultaneously. For Aurinia, this represents a material commercial risk: LUPKYNIS® is its primary revenue-generating product in a specialist nephrology market. For the broader industry, the consolidation sets up a high-stakes validity trial for two voclosporin patents that could define the competitive landscape for oral lupus nephritis therapy.
High-stakes ANDA waveFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aurinia Pharmaceuticals, Inc. | Company | Specialty biopharma company — holder of US11622991B2 and US10286036B2 covering LUPKYNIS®Search in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer filing ANDA for voclosporin (LUPKYNIS®) equivalentSearch in Eureka ↗ |
| Plaintiff counsel | C. COLLETTE CORSER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | DANIELLE A. DUSZCZYSZYN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMILY R. GABRANSKI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMMA CAPITANELLI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JUSTIN SILVERBERG | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MARK FELDSTEIN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | RYAN V. MCDONNELL | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Christine Clark | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | ERIC L. SAUNDERS | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | HEATHER M. SCHNEIDER | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | JASON N. ZACCARO | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | MICHAEL W. JOHNSON | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Selena Miriam Ellis | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | ZACHARY S. TRAVIS | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The December 3, 2025 order is purely procedural: the court found common questions of law and fact under Rule 42(a) and consolidated this action into Lead Case 25-2580 for all pre-trial purposes. Critically, no party opposed the order, suggesting all sides recognise the efficiency rationale. The order makes no finding on infringement or validity, and both Aurinia patents remain live. The substantive merits will be litigated entirely under the Lead Case docket going forward.
US11622991B2 & US10286036B2 — Voclosporin Formulations for Lupus Nephritis
US11622991B2 and US10286036B2 both protect aspects of voclosporin — a next-generation calcineurin inhibitor developed to treat active lupus nephritis with an improved tolerability profile relative to cyclosporine. LUPKYNIS® received FDA approval in January 2021 as the first oral therapy specifically indicated for lupus nephritis. The application underlying US10286036B2 was filed in 2017, establishing early priority in this therapeutic space; US11622991B2 represents a later continuation capturing additional claim coverage, consistent with a layered life-cycle management strategy.
Together, these patents form a commercially critical barrier around one of Aurinia’s sole revenue-generating products. The lupus nephritis market is relatively concentrated, making voclosporin patent exclusivity disproportionately valuable. Generic entry would expose Aurinia to immediate and substantial revenue erosion. The fact that at least two separate ANDA filers — including Teva, one of the world’s largest generic manufacturers — have challenged these patents simultaneously signals that the market considers generic entry commercially viable once the patents are defeated or expire, making the consolidated NJ litigation a defining event for the product’s lifecycle.
Should you run an FTO against US11622991B2 and US10286036B2?
Any company developing a generic, biosimilar-adjacent, or reformulated calcineurin inhibitor for nephrology or autoimmune indications should treat these two patents as mandatory FTO targets. Both are actively asserted in pending ANDA litigation, meaning the patents have been tested for enforceability in court. Even formulation-level differences from LUPKYNIS® may not be sufficient to avoid infringement without formal clearance analysis — particularly given that continuation claim sets often broaden coverage beyond the original approved formulation.
PatSnap Eureka’s FTO Search Agent can map the full voclosporin patent family, including all continuations, divisionals, and foreign counterparts, against your proposed product’s formulation and dosing parameters. Eureka’s claim-level analysis highlights which independent claims present the highest infringement risk and surfaces prior art most relevant to an invalidity challenge — enabling your IP and R&D teams to prioritise design-around strategies or invalidity arguments before committing to a full ANDA filing.
Run a freedom-to-operate analysis on US11622991B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: calcineurin inhibitors & lupus nephritis IP
Cases involving ANDA challenges to specialty drug patents in the District of New Jersey, including calcineurin inhibitor and immunosuppressant formulation disputes.
What this case signals for the lupus nephritis drug IP landscape
Multiple ANDA filings against LUPKYNIS® suggest voclosporin’s patent estate is under coordinated challenge — a pattern common when a brand drug reaches peak commercial value.
Hatch-Waxman 30-month stay gives Aurinia near-term market protection
Aurinia’s timely suit within 45 days of ANDA notice triggers a statutory 30-month stay on FDA approval of Teva’s generic. This stay runs regardless of consolidation, providing Aurinia a runway to pursue the merits in the consolidated action before any generic can enter the market — unless Teva obtains a court order shortening the stay.
Consolidation accelerates discovery but raises strategy complexity for generics
A consolidated schedule means Aurinia conducts discovery once across all defendants. For Teva and any co-defendants, this limits forum-shopping and scheduling leverage. Generic filers should expect an accelerated Markman and fact discovery timeline, consistent with NJ District Court’s active ANDA docket management practices.
Aurinia v Teva — key questions answered
The case was consolidated into Lead Case No. 25-2580 on December 3, 2025, 222 days after filing. The court found common questions of law and fact across related ANDA actions challenging Aurinia’s LUPKYNIS® (voclosporin) patents. No merits ruling has been issued; all further pre-trial proceedings occur under the Lead Case docket.
Aurinia asserted U.S. Patent Nos. 11622991B2 and 10286036B2, both covering voclosporin formulations used in its LUPKYNIS® drug product approved for lupus nephritis. The application for US10286036B2 was filed in 2017; US11622991B2 is a later-issued continuation patent, consistent with Aurinia’s lifecycle management strategy for the product.
Consolidation means Teva’s case is merged with related ANDA actions into a single pre-trial proceeding. All discovery, case management, and motion practice will proceed under Lead Case 25-2580. Teva retains all invalidity and non-infringement defences but will litigate them on a shared schedule alongside any other generic challengers rather than on an independent docket.
Yes. Consolidation is a case management mechanism and does not affect the statutory 30-month stay triggered by Aurinia’s timely lawsuit under Hatch-Waxman. The stay bars FDA from approving Teva’s ANDA during the stay period unless Teva obtains a court order shortening it or the patents are adjudged invalid or not infringed.
LUPKYNIS® is Aurinia’s FDA-approved oral calcineurin inhibitor for lupus nephritis — the first of its kind in that indication. As Aurinia’s primary commercial product, it generates substantially all of the company’s revenue. Successful generic entry by Teva would directly threaten Aurinia’s revenue base, making the patent litigation outcome of outsized financial importance relative to many ANDA disputes.
PatSnap Eureka searches patents and litigation data to answer instantly.